Soleno Therapeutics, Inc. (SLNO) Earnings History
Profitable14 years of earnings data (2012–2025) · Positive TTM net income
Loading earnings history...
Soleno Therapeutics, Inc. (SLNO) Earnings Overview
As of June 22, 2026, Soleno Therapeutics, Inc. (SLNO) reported trailing twelve-month net income of $96M, reflecting +108.9% year-over-year growth. The company earned $1.81 per diluted share over the past four quarters, with a net profit margin of 11.0%.
Looking at the long-term picture, SLNO's historical earnings data spans multiple years. The company achieved its highest annual net income of $21M in fiscal 2025, representing a new all-time high.
Soleno Therapeutics, Inc. maintains positive profitability with a gross margin of 98.6%, operating margin of 7.9%, and net margin of 11.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), ACAD ($376M net income, 36.5% margin), RYTM (-$204M net income, -103.6% margin), SLNO has outperformed on profitability metrics. Compare SLNO vs RARE →
SLNO Earnings vs Peers
Earnings metrics vs comparable public companies
SLNO Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $21M | +111.9% | $15M | $0.39 | 11.0% | 7.9% |
| 2024 | -$176M | -351.0% | -$188M | $-4.38 | - | - |
| 2023 | -$39M | -62.0% | -$41M | $-2.36 | - | - |
| 2022 | -$24M | +22.1% | -$24M | $-2.87 | - | - |
| 2021 | -$31M | -25.5% | -$32M | $-5.81 | - | - |
| 2020 | -$25M | +19.9% | -$32M | $-3.68 | - | - |
| 2019 | -$31M | -130.8% | -$23M | $-15.78 | - | - |
| 2018 | -$13M | +14.9% | -$14M | $-9.54 | - | - |
| 2017 | -$16M | -29.9% | -$12M | $-26.18 | - | - |
| 2016 | -$12M | +24.2% | -$14M | $-58.35 | -831.6% | -938.1% |
| 2015 | -$16M | -14.7% | -$12M | $-126.58 | -4104.8% | -3137.6% |
| 2014 | -$14M | -274.3% | -$5M | $-819.38 | - | - |
| 2013 | -$4M | +42.8% | $-846,783 | $-198.45 | -123.6% | -28.2% |
| 2012 | -$6M | - | -$4M | $-346.98 | - | - |
Download Data
Export SLNO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
What is SLNO earnings per share (EPS)?
SLNO trailing twelve-month (TTM) diluted EPS is $1.81, reflecting +108.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Soleno Therapeutics, Inc.'s net income?
Soleno Therapeutics, Inc. (SLNO) trailing twelve-month net income is $96M as of 2025. Earnings grew +108.9% year-over-year.
Is SLNO profitable?
Yes, SLNO is profitable with a TTM net income of $96M and a net profit margin of +11.0%.
What is SLNO's earnings growth rate?
SLNO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are SLNO's profit margins?
Soleno Therapeutics, Inc. net profit margin is +11.0%, operating margin is +7.9%, and gross margin is +98.6%. Margins are within a typical range for the sector. Return on Equity is +6.0%.
Is SLNO growing earnings?
Yes, SLNO earnings are accelerating — EPS growth of +108.9% exceeds the 5-year CAGR of N/A. TTM net income reached $96M. Earnings momentum is strengthening.
What was SLNO's best earnings year?
Soleno Therapeutics, Inc.'s highest annual net income on record is $21M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were SLNO's earnings last quarter?
SLNO's most recent reported quarter was Q1 2026. Net income was $31M with diluted EPS of $0.59. For a full breakdown of all quarters, see the quarterly earnings table on this page.